These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3155299)

  • 1. GH secretory dynamics and responsiveness to SMS 201-995 treatment in acromegaly.
    Kim SW; Kim SY; Yang IM; Kim JW; Kim YS; Kim KW; Choi YK
    Korean J Intern Med; 1988 Jul; 3(2):110-6. PubMed ID: 3155299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of long acting somatostatin analogue SMS 201-995 in acromegaly.
    Choi CJ; Shin DB; Kim SW; Yang IM; Kim JW; Kim YS; Choi YK
    Korean J Intern Med; 1987 Jul; 2(2):176-83. PubMed ID: 3155325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects on growth hormone secretion of a new somatostatin analogue (SMS 201-995) and nonspecific releasing hormones in patients with acromegaly].
    Candrina R
    Medicina (Firenze); 1988; 8(2):180-1. PubMed ID: 3147351
    [No Abstract]   [Full Text] [Related]  

  • 4. Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormone.
    Hofland LJ; van Koetsveld PM; van Vroonhoven CC; Stefanko SZ; Lamberts SW
    J Clin Endocrinol Metab; 1989 Mar; 68(3):613-20. PubMed ID: 2493040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The growth hormone (GH) response to GH-releasing peptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2), GH-releasing hormone, and thyrotropin-releasing hormone in acromegaly.
    Alster DK; Bowers CY; Jaffe CA; Ho PJ; Barkan AL
    J Clin Endocrinol Metab; 1993 Sep; 77(3):842-5. PubMed ID: 8370708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
    Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
    J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does SMS 201-995 normalize growth hormone secretion in acromegaly? GH day profiles and GH concentrations after oral glucose loading.
    van Liessum PA; Pieters GF; Smals AG; Swinkels LM; Benraad TJ; Kloppenborg PW
    J Endocrinol Invest; 1989 Sep; 12(8):553-7. PubMed ID: 2592740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration.
    Candrina R
    Recenti Prog Med; 1991 Jan; 82(1):13-6. PubMed ID: 1902962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Response of growth hormone to the acute test using GH-releasing factor 1-29 in acromegaly. Comparison in the baseline situation and under treatment with prolonged-action somatostatin].
    Gavilán I; Santos C; García-Luna PP; Acosta D; Leal-Cerro A; Navarro E; Fernández-López I; Astorga R
    Rev Clin Esp; 1988 Mar; 182(4):187-91. PubMed ID: 2901136
    [No Abstract]   [Full Text] [Related]  

  • 11. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
    Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
    J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of octreotide on 24-h blood pressure profile in acromegaly.
    Fallo F; Barzon L; Boscaro M; Casiglia E; Sonino N
    Am J Hypertens; 1998 May; 11(5):591-6. PubMed ID: 9633796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pirenzepine, bromocriptine and their association on basal and GHRH- and TRH-induced GH secretion in acromegaly.
    Fiszlejder L; Penacini O; Ratz S; Storani M; Oneto A; Guitelman A
    Horm Res; 1991; 36(1-2):47-51. PubMed ID: 1814801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
    Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
    J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly.
    Comi RJ; Gorden P
    J Clin Endocrinol Metab; 1987 Jan; 64(1):37-42. PubMed ID: 2878009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of octreotide on 24-hour growth hormone and prolactin secretory patterns in acromegalics.
    Schindel B; Ashkenazi I; Keret R; Silbergeld A; Wasserman M; Lapidot M; Harris AG; Laron Z
    Horm Res; 1991; 36(5-6):209-15. PubMed ID: 1823080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretory mechanisms of growth hormone (GH)-releasing peptide-, GH-releasing hormone-, and thyrotropin-releasing hormone-induced GH release in patients with acromegaly.
    Hanew K; Utsumi A; Tanaka A; Ikeda H; Yokogoshi Y
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3578-83. PubMed ID: 9768668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased growth hormone pulse frequency in acromegaly.
    Barkan AL; Stred SE; Reno K; Markovs M; Hopwood NJ; Kelch RP; Beitins IZ
    J Clin Endocrinol Metab; 1989 Dec; 69(6):1225-33. PubMed ID: 2511221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
    Gasińska T; Nowak S
    Endokrynol Pol; 1993; 44(4):455-65. PubMed ID: 8055814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.